TY - JOUR
T1 - Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer
AU - Ueda, Masami
AU - Iguchi, Tomohiro
AU - Masuda, Takaaki
AU - Komatsu, Hisateru
AU - Nambara, Sho
AU - Sakimura, Shotaro
AU - Hirata, Hidenari
AU - Uchi, Ryutaro
AU - Eguchi, Hidetoshi
AU - Ito, Shuhei
AU - Sugimachi, Keishi
AU - Mizushima, Tsunekazu
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Mimori, Koshi
PY - 2017/5
Y1 - 2017/5
N2 - Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.
AB - Background/Aim: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC). Materials and Methods: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments. Results: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorageindependent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro. Conclusion: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC.
UR - http://www.scopus.com/inward/record.url?scp=85019136447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019136447&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11562
DO - 10.21873/anticanres.11562
M3 - Article
C2 - 28476790
AN - SCOPUS:85019136447
SN - 0250-7005
VL - 37
SP - 2255
EP - 2263
JO - Anticancer research
JF - Anticancer research
IS - 5
ER -
